Cargando…
Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks
OBJECTIVES: This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Turkish League Against Rheumatism
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140873/ https://www.ncbi.nlm.nih.gov/pubmed/34046569 http://dx.doi.org/10.46497/ArchRheumatol.2021.7806 |
_version_ | 1783696263955349504 |
---|---|
author | KARKUCAK, Murat KOLA, Mehmet KALKIŞIM, Ahmet ÇAPKIN, Erhan AYAR, Ahmet TÜRK, Adem |
author_facet | KARKUCAK, Murat KOLA, Mehmet KALKIŞIM, Ahmet ÇAPKIN, Erhan AYAR, Ahmet TÜRK, Adem |
author_sort | KARKUCAK, Murat |
collection | PubMed |
description | OBJECTIVES: This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab therapy. PATIENTS AND METHODS: October 2014 and March 2016 Thirty-one patients with AS (22 males, 9 females; mean age 39.6±12.3 years; range, 22 to 68 years) and 24 healthy controls (16 males, 8 females; mean age 40.8±8.9 years; range, 35 to 61 years) were enrolled. Patients’ clinical and demographic characteristics were recorded. Using OCT, we performed retinal nerve fiber layer (RNFL) thickness, ganglion cell complex, and ChT measurements in AS patients before and six months after the initiation of infliximab therapy, and in healthy controls. RESULTS: At baseline, patients with AS had higher ChT (mean±standard deviation: 347.5±114.4 μm) compared to healthy controls (322.1±62.8 μm), although this did not reach statistical significance level (p=0.283). At six months after the first measurement, the mean ChT was significantly decreased (under infliximab therapy: 326.5±99.7 μm vs. before: 347.5±114.4 μm, p=0.018) in AS group, while no significant change was observed in the control group (p=0.102). RNFL thickness in the AS group was significantly decreased after six months of treatment with infliximab (p=0.008). CONCLUSION: By evaluating the posterior eye segment of patients with AS using OCT, this study has demonstrated that active AS patients had higher ChT. The significant reduction in this ChT after infliximab therapy may be mediating the established effective suppressing action of infliximab on uveitis attacks. |
format | Online Article Text |
id | pubmed-8140873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Turkish League Against Rheumatism |
record_format | MEDLINE/PubMed |
spelling | pubmed-81408732021-05-26 Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks KARKUCAK, Murat KOLA, Mehmet KALKIŞIM, Ahmet ÇAPKIN, Erhan AYAR, Ahmet TÜRK, Adem Arch Rheumatol Original Article OBJECTIVES: This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab therapy. PATIENTS AND METHODS: October 2014 and March 2016 Thirty-one patients with AS (22 males, 9 females; mean age 39.6±12.3 years; range, 22 to 68 years) and 24 healthy controls (16 males, 8 females; mean age 40.8±8.9 years; range, 35 to 61 years) were enrolled. Patients’ clinical and demographic characteristics were recorded. Using OCT, we performed retinal nerve fiber layer (RNFL) thickness, ganglion cell complex, and ChT measurements in AS patients before and six months after the initiation of infliximab therapy, and in healthy controls. RESULTS: At baseline, patients with AS had higher ChT (mean±standard deviation: 347.5±114.4 μm) compared to healthy controls (322.1±62.8 μm), although this did not reach statistical significance level (p=0.283). At six months after the first measurement, the mean ChT was significantly decreased (under infliximab therapy: 326.5±99.7 μm vs. before: 347.5±114.4 μm, p=0.018) in AS group, while no significant change was observed in the control group (p=0.102). RNFL thickness in the AS group was significantly decreased after six months of treatment with infliximab (p=0.008). CONCLUSION: By evaluating the posterior eye segment of patients with AS using OCT, this study has demonstrated that active AS patients had higher ChT. The significant reduction in this ChT after infliximab therapy may be mediating the established effective suppressing action of infliximab on uveitis attacks. Turkish League Against Rheumatism 2020-09-04 /pmc/articles/PMC8140873/ /pubmed/34046569 http://dx.doi.org/10.46497/ArchRheumatol.2021.7806 Text en Copyright © 2020, Turkish League Against Rheumatism https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Article KARKUCAK, Murat KOLA, Mehmet KALKIŞIM, Ahmet ÇAPKIN, Erhan AYAR, Ahmet TÜRK, Adem Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks |
title | Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks |
title_full | Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks |
title_fullStr | Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks |
title_full_unstemmed | Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks |
title_short | Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks |
title_sort | infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: a possible mechanism mediating the suppressing of uveitis attacks |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140873/ https://www.ncbi.nlm.nih.gov/pubmed/34046569 http://dx.doi.org/10.46497/ArchRheumatol.2021.7806 |
work_keys_str_mv | AT karkucakmurat infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks AT kolamehmet infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks AT kalkisimahmet infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks AT capkinerhan infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks AT ayarahmet infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks AT turkadem infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks |